Tarsus Pharmaceuticals Inc. (TARS)
TARS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$70.82
-4.81% on the day
Market cap
$3.3B
Mid cap
Revenue · 2025
$451.4M
+146.7% on 2024
Net income · 2025
-$66.0M
-14.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | TARS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001819790 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $451.4M |
| Net income | -$66.0M |
| Operating income | -$71.0M |
| Net margin | -14.6% |
| Operating margin | -15.7% |
| Revenue growth | +146.7% |
| Cash | $183.6M |
| Total assets | $562.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-10-13 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K/A | 2026-10-13 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 671 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.2% |
| 1 month | -7.1% |
| 3 months | +26.0% |
| Year to date | -11.2% |
| 1 year | +3.4% |
| From 52-week high | -19.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $18.40 | -2.90% | $2.9B |
| RLAY | Relay Therapeutics Inc. | $17.36 | -3.45% | $3.8B |
| ADPT | Adaptive Biotechnologies Corporation | $25.28 | -1.13% | $4.0B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| CRSP | CRISPR Therapeutics AG Common Shares | $50.10 | -2.81% | $4.8B |
| SRRK | Scholar Rock Holding Corporation | $40.52 | -3.39% | $4.9B |
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier